Pfizer is a global leader in discovering and developing medicines for patients suffering from chronic immune diseases. Pfizer is committed to the discovery and development of novel therapeutics to help patients living with chronic autoimmune diseases. Pfizer Inflammation & Immunology is focused on discovering and developing the next generation of therapies for immune- mediated diseases. Pfizer is interested in entering into strategic relationships with innovative collaborators to develop novel and differentiated therapies for autoimmune diseases.
We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact three main areas:
Rheumatology
Rheumatoid Arthritis
Systemic Lupus Erythematosus/lupus nephritis
Gastroenterology/Hepatology
Inflammatory Bowel Disease
Nonalcoholic steatohepatitis (NASH)
Medical Dermatology
Atopic Dermatitis
Psoriasis
Alopecia
Vitiligo
Other indications with high unmet need that are related to those above
Specific areas of interest include:
Cytokines and their signaling pathways
Adaptive Immunity, Lymphocyte biology including Th17 lymphocytes
Regulatory cells and Tolerance induction
Host-microbial interactions and microbiome with an interest in epithelial barrier
Leukocyte metabolism
Innate Immunity and Innate Lymphoid Cell biology
Oxidative stress modulators
Anti-fibrotics
Technology platforms and products to help understand patient segmentation in the disease areas of interest and develop precision medicine strategies for innovative portfolio products
Technology platforms and products that allow for greater tissue and cell specific delivery